Cachexia in pancreatic cancer: new treatment options and measures of success.
作者信息
Fearon Kenneth C H, Baracos Vickie E
出版信息
HPB (Oxford). 2010 Jun;12(5):323-4. doi: 10.1111/j.1477-2574.2010.00178.x.
Abstract
摘要
相似文献
1
Cachexia in pancreatic cancer: new treatment options and measures of success.
HPB (Oxford). 2010 Jun;12(5):323-4. doi: 10.1111/j.1477-2574.2010.00178.x.
2
Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's procedure.
HPB (Oxford). 2010 Jun;12(5):325-33. doi: 10.1111/j.1477-2574.2010.00171.x.
3
Cachexia worsens prognosis in patients with resectable pancreatic cancer.
J Gastrointest Surg. 2008 Jul;12(7):1193-201. doi: 10.1007/s11605-008-0505-z. Epub 2008 Mar 18.
4
Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function.
BMC Cancer. 2009 Jul 28;9:255. doi: 10.1186/1471-2407-9-255.
5
Cachexia and pancreatic cancer: are there treatment options?
World J Gastroenterol. 2014 Jul 28;20(28):9361-73. doi: 10.3748/wjg.v20.i28.9361.
6
Ductal adenocarcinoma of the pancreatic head: a focus on current diagnostic and surgical concepts.
World J Gastroenterol. 2012 Jun 28;18(24):3058-69. doi: 10.3748/wjg.v18.i24.3058.
7
Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions.
Pancreas. 2017 Oct;46(9):1152-1157. doi: 10.1097/MPA.0000000000000898.
8
Treatment strategy of intraductal papillary-mucinous tumor of the pancreas.
J Gastroenterol. 2005 Jul;40(7):773-4. doi: 10.1007/s00535-005-1648-2.
9
Nutritional and immune impairments and their effects on outcomes in early pancreatic cancer patients undergoing pancreatoduodenectomy.
Clin Nutr. 2020 Nov;39(11):3385-3394. doi: 10.1016/j.clnu.2020.02.029. Epub 2020 Mar 6.
10
Prognosis of invasive intraductal papillary mucinous neoplasm.
Pancreas. 2008 Oct;37(3):333; author reply 333-4. doi: 10.1097/mpa.0b013e31816a4f1d.
引用本文的文献
1
Effects of parenteral nutrition + best supportive nutritional care vs. best supportive nutritional care alone on quality of life in patients with pancreatic cancer-a secondary analysis of PANUSCO.
Support Care Cancer. 2024 Jun 27;32(7):466. doi: 10.1007/s00520-024-08666-1.
2
Pancreatic Exocrine Insufficiency and the Gut Microbiome in Pancreatic Cancer: A Target for Future Diagnostic Tests and Therapies?
Cancers (Basel). 2023 Oct 25;15(21):5140. doi: 10.3390/cancers15215140.
3
Recent Advances in Pancreatic Ductal Adenocarcinoma: Strategies to Optimise the Perioperative Nutritional Status in Pancreatoduodenectomy Patients.
Cancers (Basel). 2023 Apr 25;15(9):2466. doi: 10.3390/cancers15092466.
4
Nutritional Interventions in Pancreatic Cancer: A Systematic Review.
Cancers (Basel). 2022 Apr 28;14(9):2212. doi: 10.3390/cancers14092212.
5
Evaluation of a protocol to detect malnutrition and provide nutritional care for cancer patients undergoing chemotherapy.
Sci Rep. 2020 Dec 3;10(1):21186. doi: 10.1038/s41598-020-78246-w.
6
Mathematical Model of Muscle Wasting in Cancer Cachexia.
J Clin Med. 2020 Jun 28;9(7):2029. doi: 10.3390/jcm9072029.
7
Dual Energy X-ray Absorptiometry (DEXA) as a longitudinal outcome measure of cancer-related muscle wasting in mice.
PLoS One. 2020 Jun 19;15(6):e0230695. doi: 10.1371/journal.pone.0230695. eCollection 2020.
8
Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia.
J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):619-635. doi: 10.1002/jcsm.12528. Epub 2020 Mar 6.
9
Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer.
Cancers (Basel). 2020 Jan 22;12(2):275. doi: 10.3390/cancers12020275.
10
The Role of Systemic Inflammation in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention.
JCSM Clin Rep. 2018 Jul-Dec;3(2).
本文引用的文献
1
Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's procedure.
HPB (Oxford). 2010 Jun;12(5):325-33. doi: 10.1111/j.1477-2574.2010.00171.x.
2
Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer.
Clin Cancer Res. 2009 Nov 15;15(22):6973-9. doi: 10.1158/1078-0432.CCR-09-1525. Epub 2009 Nov 3.
3
Associations between physical activity and quality of life in cancer patients receiving palliative care: a pilot survey.
J Pain Symptom Manage. 2009 Nov;38(5):785-96. doi: 10.1016/j.jpainsymman.2009.03.006. Epub 2009 Sep 23.
4
The emerging role of computerized tomography in assessing cancer cachexia.
Curr Opin Support Palliat Care. 2009 Dec;3(4):269-75. doi: 10.1097/SPC.0b013e328331124a.
5
Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function.
BMC Cancer. 2009 Jul 28;9:255. doi: 10.1186/1471-2407-9-255.
6
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Clin Cancer Res. 2009 Apr 15;15(8):2920-6. doi: 10.1158/1078-0432.CCR-08-2242. Epub 2009 Apr 7.
7
A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care.
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006. doi: 10.1139/H08-075.
8
Cancer cachexia: developing multimodal therapy for a multidimensional problem.
Eur J Cancer. 2008 May;44(8):1124-32. doi: 10.1016/j.ejca.2008.02.033. Epub 2008 Mar 28.
9
Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity.
Clin Cancer Res. 2007 Jun 1;13(11):3264-8. doi: 10.1158/1078-0432.CCR-06-3067.
10
Research methodology: cancer cachexia syndrome.
Palliat Med. 2004 Jul;18(5):409-17. doi: 10.1191/0269216304pm906ra.
Zotero 插件